ドラベット症候群治療薬の世界市場:疫学予測

◆英語タイトル:Dravet Syndrome - Epidemiology Forecast to 2030
◆商品コード:DELV20JU193
◆発行会社(リサーチ会社):DelveInsight
◆発行日:2020年7月
◆ページ数:100
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後2営業日)
◆調査対象地域:アメリカ、ヨーロッパ、日本
◆販売価格オプション(消費税別)
Single User(193名様閲覧)USD3,750 ⇒換算¥393,750見積依頼/購入/質問フォーム
Three UserUSD5,625 ⇒換算¥590,625見積依頼/購入/質問フォーム
Site LicenseUSD7,500 ⇒換算¥787,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はDelveInsight社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
DelveInsight社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

DelveInsight’s ‘Dravet Syndrome – Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Dravet Syndrome epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Geographies Covered
The United States
EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Japan
Study Period: 2017–2030
Dravet Syndrome Understanding
The DelveInsight Dravet Syndrome epidemiology report gives a thorough understanding of the Dravet Syndrome by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Dravet Syndrome in the US, Europe, and Japan. The report covers the detailed information of the Dravet Syndrome epidemiology scenario in seven major countries (US, EU5, and Japan).

Dravet Syndrome Epidemiology Perspective by DelveInsight
The Dravet Syndrome epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Dravet Syndrome epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Dravet Syndrome epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Dravet Syndrome Detailed Epidemiology Segmentation
The Dravet Syndrome epidemiology covered in the report provides historical as well as forecasted Dravet Syndrome epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.

The DelveInsight Dravet Syndrome report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report
The Dravet Syndrome report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
The Dravet Syndrome Epidemiology Report and Model provide an overview of the global trends of Dravet Syndrome in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
The report provides insight into the historical and forecasted patient pool of Dravet Syndrome in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
The report assesses the disease risk and burden and highlights the unmet needs of Dravet Syndrome
The report provides the segmentation of the Dravet Syndrome epidemiology
Report Highlights
11-year Forecast of Dravet Syndrome epidemiology
7MM Coverage
Incidence and Diagnosed Cases of Dravet Syndrome
Mutation positive cases of Dravet Syndrome
Mutation cases by class and types
Seizure associated cases of Dravet Syndrome
Gender-specific cases of Dravet Syndrome
Age-specific cases of Dravet Syndrome
KOL Views
We interview, KOLs and SME’s opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered
What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Dravet Syndrome?
What are the key findings pertaining to the Dravet Syndrome epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017–2030)?
What would be the total number of patients of Dravet Syndrome across the 7MM during the forecast period (2017–2030)?
Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017–2030)?
At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017–2030)?
What is the disease risk, burden and unmet needs of Dravet Syndrome?
What are the currently available treatments of Dravet Syndrome?
Reasons to buy
The Dravet Syndrome Epidemiology report will allow the user to -
Develop business strategies by understanding the trends shaping and driving the global Dravet Syndrome market
Quantify patient populations in the global Dravet Syndrome market to improve product design, pricing, and launch plans
Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Dravet Syndrome therapeutics in each of the markets covered
Understand the magnitude of Dravet Syndrome population by its epidemiology
The Dravet Syndrome Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources
Key Assessments
Patient Segmentation
Disease Risk & Burden
Risk of disease by the segmentation
Factors driving growth in a specific patient population

【レポートの目次】

1 Key Insights

2 Executive Summary of Dravet Syndrome

3 SWOT Analysis for Dravet Syndrome

4 Dravet Syndrome Market Overview at a Glance

4.1 Market Share (%) Distribution of Dravet Syndrome in 2017

4.2 Market Share (%) Distribution of Dravet Syndrome in 2030

5 Dravet Syndrome: Disease Background and Overview

5.1 Introduction

5.2 Clinical Features of Dravet Syndrome

5.2.1 Epilepsy

5.2.2 Cognition

5.2.3 Movement disorders

5.2.4 Sudden Death

5.3 Genetics of Dravet Syndrome

5.3.1 Sodium Channel a1 Subunit Gene (SCN1A) and its association with Dravet Syndrome

5.3.2 Functional aspects of voltage gate sodium channel mutations

5.3.3 Detection of SCN1A mutations

5.3.4 Inheritance mode and pattern

5.3.5 Dravet Syndrome without SCN1A Alterations

5.4 Signs and Symptoms of Dravet Syndrome

5.5 Pathophysiology

5.6 Diagnosis of Dravet Syndrome

5.6.1 Differential diagnosis

6 Epidemiology and Patient Population

6.1 Key Findings

6.2 Total Incidence of Dravet Syndrome in 7MM

7 Country-wise Epidemiology of Dravet Syndrome

8 United States

8.1 Assumptions and Rationale

8.2 Incident Population of Dravet Syndrome

8.3 Mutations associated with Dravet Syndrome

8.3.1 Incidence of Dravet Syndrome by Mutation Class

8.3.2 Incidence of Dravet Syndrome by Mutation Type

8.4 Seizure associated cases of Dravet Syndrome

8.5 Gender-specific Incidence of Dravet Syndrome

8.6 Age-specific Incidence of Dravet Syndrome

9 EU-5

9.1 Assumptions and Rationale

10 Germany

10.1 Incident Population of Dravet Syndrome

10.2 Mutations associated with Dravet Syndrome

10.2.1 Incidence of Dravet Syndrome by Mutation Class

10.2.2 Incidence of Dravet Syndrome by Mutation Type

10.3 Seizure associated cases of Dravet Syndrome

10.4 Gender-specific Incidence of Dravet Syndrome

10.5 Age-specific Incidence of Dravet Syndrome

11 France

11.1 Incident Population of Dravet Syndrome

11.2 Mutations associated with Dravet Syndrome

11.2.1 Incidence of Dravet Syndrome by Mutation Class

11.2.2 Incidence of Dravet Syndrome by Mutation Type

11.3 Seizure associated cases of Dravet Syndrome

11.4 Gender-specific Incidence of Dravet Syndrome

11.5 Age-specific Incidence of Dravet Syndrome

12 Italy

12.1 Incident Population of Dravet Syndrome

12.2 Mutations associated with Dravet Syndrome

12.2.1 Incidence of Dravet Syndrome by Mutation Class

12.2.2 Incidence of Dravet Syndrome by Mutation Type

12.3 Seizure associated cases of Dravet Syndrome

12.4 Gender-specific Incidence of Dravet Syndrome

12.5 Age-specific Incidence of Dravet Syndrome

13 Spain

13.1 Incident Population of Dravet Syndrome

13.2 Mutations associated with Dravet Syndrome

13.2.1 Incidence of Dravet Syndrome by Mutation Class

13.2.2 Incidence of Dravet Syndrome by Mutation Type.

13.3 Seizure associated cases of Dravet Syndrome

13.4 Gender-specific Incidence of Dravet Syndrome

13.5 Age-specific Incidence of Dravet Syndrome

14 United Kingdom

14.1 Incident Population of Dravet Syndrome

14.2 Mutations associated with Dravet Syndrome

14.2.1 Incidence of Dravet Syndrome by Mutation Class

14.2.2 Incidence of Dravet Syndrome by Mutation Type

14.3 Seizure associated cases of Dravet Syndrome

14.4 Gender-specific Incidence of Dravet Syndrome

14.5 Age-specific Incidence of Dravet Syndrome

15 Japan

15.1 Assumptions and Rationale

15.2 Incident Population of Dravet Syndrome

15.3 Mutations associated with Dravet Syndrome

15.3.1 Incidence of Dravet Syndrome by Mutation Class

15.3.2 Incidence of Dravet Syndrome by Mutation Type

15.4 Seizure associated cases of Dravet Syndrome

15.5 Gender-specific Incidence of Dravet Syndrome

15.6 Age-specific Incidence of Dravet Syndrome

16 Treatment of Dravet Syndrome

16.1 Current Treatment Practices

16.1.1 First-Line Therapies: Valproic Acid and Clobazam

16.1.2 Second-Line Therapies

16.1.3 Third Line of Therapies

16.2 Treatment Algorithm

17 Unmet Needs

18 Organizations contributing toward Dravet Syndrome

19 KOL’s Views: Dravet Syndrome

20 Case Studies

21 Appendix

22 Report Methodology

22.1 Sources Used

23 DelveInsight Capabilities

24 Disclaimer

25 About DelveInsight

Table 1: Genetic background of Dravet syndrome

Table 2: Total Incident Population of Dravet Syndrome in 7MM (2017–2030)

Table 3: Incident Population of Dravet Syndrome in the United States (2017–2030)

Table 4: Mutation positive cases of Dravet Syndrome in the United States (2017–2030)

Table 5: Incidence of Dravet Syndrome by Mutation Class in the United States (2017–2030)

Table 6: Incidence of Dravet Syndrome by Mutation Type in the United States (2017–2030)

Table 7: Seizure associated cases of Dravet Syndrome in the United States (2017–2030)

Table 8: Gender-specific Incidence of Dravet Syndrome in the United States (2017–2030)

Table 9: Age-specific Incidence of Dravet Syndrome in the United States (2017–2030)

Table 10: Incident Population of Dravet Syndrome in Germany (2017–2030)

Table 11: Mutation positive cases of Dravet Syndrome in Germany (2017–2030)

Table 12: Incidence of Dravet Syndrome by Mutation Class in Germany (2017–2030)

Table 13: Incidence of Dravet Syndrome by Mutation Type in Germany (2017–2030)

Table 14: Seizure associated cases of Dravet Syndrome in Germany (2017–2030)

Table 15: Gender-specific Incidence of Dravet Syndrome in Germany (2017–2030)

Table 16: Age-specific Incidence of Dravet Syndrome in Germany (2017–2030)

Table 17: Incident Population of Dravet Syndrome in France (2017–2030)

Table 18: Mutation positive cases of Dravet Syndrome in France (2017–2030)

Table 19: Incidence of Dravet Syndrome by Mutation Class in France (2017–2030)

Table 20: Incidence of Dravet Syndrome by Mutation Type in France (2017–2030)

Table 21: Seizure associated cases of Dravet Syndrome in France (2017–2030)

Table 22: Gender-specific Incidence of Dravet Syndrome in France (2017–2030)

Table 23: Age-specific Incidence of Dravet Syndrome in France (2017–2030)

Table 24: Incident Population of Dravet Syndrome in Italy (2017–2030)

Table 25: Mutation positive cases of Dravet Syndrome in Italy (2017–2030)

Table 26: Incidence of Dravet Syndrome by Mutation Class in Italy (2017–2030)

Table 27: Incidence of Dravet Syndrome by Mutation Type in Italy (2017–2030)

Table 28: Seizure associated cases of Dravet Syndrome in Italy (2017–2030)

Table 29: Gender-specific Incidence of Dravet Syndrome in Italy (2017–2030)

Table 30: Age-specific Incidence of Dravet Syndrome in Italy (2017–2030)

Table 31: Incident Population of Dravet Syndrome in Spain (2017–2030)

Table 32: Mutation positive cases of Dravet Syndrome in Spain (2017–2030)

Table 33: Incidence of Dravet Syndrome by Mutation Class in Spain (2017–2030)

Table 34: Incidence of Dravet Syndrome by Mutation Type in Spain (2017–2030)

Table 35: Seizure associated cases of Dravet Syndrome in Spain (2017–2030)

Table 36: Gender-specific Incidence of Dravet Syndrome in Spain (2017–2030)

Table 37: Age-specific Incidence of Dravet Syndrome in Spain (2017–2030)

Table 38: Incident Population of Dravet Syndrome in the United Kingdom (2017–2030)

Table 39: Mutation positive cases of Dravet Syndrome in the United Kingdom (2017–2030)

Table 40: Incidence of Dravet Syndrome by Mutation Class in the United Kingdom (2017–2030)

Table 41: Incidence of Dravet Syndrome by Mutation Type in the United Kingdom (2017–2030)

Table 42: Seizure associated cases of Dravet Syndrome in the United Kingdom (2017–2030)

Table 43: Gender-specific Incidence of Dravet Syndrome in the United Kingdom (2017–2030)

Table 44: Age-specific Incidence of Dravet Syndrome in the United Kingdom (2017–2030)

Table 45: Incident Population of Dravet Syndrome in Japan (2017–2030)

Table 46: Mutation positive cases of Dravet Syndrome in Japan (2017–2030)

Table 47: Incidence of Dravet Syndrome by Mutation Class in Japan (2017–2030)

Table 48: Incidence of Dravet Syndrome by Mutation Type in Japan (2017–2030)

Table 49: Seizure associated cases of Dravet Syndrome in Japan (2017–2030)

Table 50: Gender-specific Incidence of Dravet Syndrome in Japan (2017–2030)

Table 51: Age-specific Incidence of Dravet Syndrome in Japan (2017–2030)

Table 52: Organizations contributing to Dravet Syndrome

List of Figures

Figure 1: Schematic representation of the clinical manifestations of Dravet syndrome

Figure 2: Differential diagnosis of Dravet syndrome in the course of the disease

Figure 3: Total Incident Population of Dravet Syndrome in 7MM (2017–2030)

Figure 4: Incident Population of Dravet Syndrome in the United States (2017–2030)

Figure 5: Mutation positive cases of Dravet Syndrome in the United States (2017–2030)

Figure 6: Incidence of Dravet Syndrome by Mutation Class in the United States (2017–2030)

Figure 7: Incidence of Dravet Syndrome by Mutation Type in the United States (2017–2030)

Figure 8: Seizure associated cases of Dravet Syndrome in the United States (2017–2030)

Figure 9: Gender-specific Incidence of Dravet Syndrome in the United States (2017–2030)

Figure 10: Age-specific Incidence of Dravet Syndrome in the United States (2017–2030)

Figure 11: Incident Population of Dravet Syndrome in Germany (2017–2030)

Figure 12: Mutation positive cases of Dravet Syndrome in Germany (2017–2030)

Figure 13: Incidence of Dravet Syndrome by Mutation Class in Germany (2017–2030)

Figure 14: Incidence of Dravet Syndrome by Mutation Type in Germany (2017–2030)

Figure 15: Seizure associated cases of Dravet Syndrome in Germany (2017–2030)

Figure 16: Gender-specific Incidence of Dravet Syndrome in Germany (2017–2030)

Figure 17: Age-specific Incidence of Dravet Syndrome in Germany 2017–2030)

Figure 18: Incident Population of Dravet Syndrome in France (2017–2030)

Figure 19: Mutation positive cases of Dravet Syndrome in France (2017–2030)

Figure 20: Incidence of Dravet Syndrome by Mutation Class in France (2017–2030)

Figure 21: Incidence of Dravet Syndrome by Mutation Type in France (2017–2030)

Figure 22: Seizure associated cases of Dravet Syndrome in France (2017–2030)

Figure 23: Gender-specific Incidence of Dravet Syndrome in France (2017–2030)

Figure 24: Age-specific Incidence of Dravet Syndrome in France (2017–2030)

Figure 25: Incident Population of Dravet Syndrome in Italy (2017–2030)

Figure 26: Mutation positive cases of Dravet Syndrome in Italy (2017–2030)

Figure 27: Incidence of Dravet Syndrome by Mutation Class in Italy (2017–2030)

Figure 28: Incidence of Dravet Syndrome by Mutation Type in Italy (2017–2030)

Figure 29: Seizure associated cases of Dravet Syndrome in Italy (2017–2030)

Figure 30: Gender-specific Incidence of Dravet Syndrome in Italy (2017–2030)

Figure 31: Age-specific Incidence of Dravet Syndrome in Italy (2017–2030)

Figure 32: Incident Population of Dravet Syndrome in Spain (2017–2030)

Figure 33: Mutation positive cases of Dravet Syndrome in Spain (2017–2030)

Figure 34: Incidence of Dravet Syndrome by Mutation Class in Spain (2017–2030)

Figure 35: Incidence of Dravet Syndrome by Mutation Type in Spain (2017–2030)

Figure 36: Seizure associated cases of Dravet Syndrome in Spain (2017–2030)

Figure 37: Gender-specific Incidence of Dravet Syndrome in Spain (2017–2030)

Figure 38: Age-specific Incidence of Dravet Syndrome in Spain (2017–2030)

Figure 39: Incident Population of Dravet Syndrome in the United Kingdom (2017–2030)

Figure 40: Mutation positive cases of Dravet Syndrome in the United Kingdom (2017–2030)

Figure 41: Incidence of Dravet Syndrome by Mutation Class in the United Kingdom (2017–2030)

Figure 42: Incidence of Dravet Syndrome by Mutation Type in the United Kingdom (2017–2030)

Figure 43: Seizure associated cases of Dravet Syndrome in the United Kingdom (2017–2030)

Figure 44: Gender-specific Incidence of Dravet Syndrome in the United Kingdom (2017–2030)

Figure 45: Age-specific Incidence of Dravet Syndrome in the United Kingdom (2017–2030)

Figure 46: Incident Population of Dravet Syndrome in Japan (2017–2030)

Figure 47: Mutation positive cases of Dravet Syndrome in Japan (2017–2030)

Figure 48: Incidence of Dravet Syndrome by Mutation Class in Japan (2017–2030)

Figure 49: Incidence of Dravet Syndrome by Mutation Type in Japan (2017–2030)

Figure 50: Seizure associated cases of Dravet Syndrome in Japan (2017–2030)

Figure 51: Gender-specific Incidence of Dravet Syndrome in Japan (2017–2030)

Figure 52: Age-specific Incidence of Dravet Syndrome in Japan (2017–2030)

Figure 53: Treatment algorithm of epilepsy in Dravet syndrome.

Figure 54: Unmet Needs for Dravet Syndrome

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[ドラベット症候群治療薬の世界市場:疫学予測]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆